Neurologic clinical trials - Argenx - 113 Study 102540

Status:

In Process (Study opening soon)

ClinicalTrials.gov:

NCT03669588

This is a randomized, double-blind, placebo controlled, multicenter Phase 3 trial to evaluate the efficacy, safety, tolerability, quality of life and impact on normal daily activities of ARGX-113 in patients with gMG.

Drug

Biological: ARGX-113, placebo

Trial Type

Interventional

Age Range

18 years or older

Condition

Myasthenia gravis

Keywords

ARGX-113 | Generalized Myasthenia Gravis (gMG) | Argenx